Protara Therapeutics (TARA) Non Operating Income (2013 - 2026)

Protara Therapeutics (TARA) has reported Non Operating Income for 14 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 16.43% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $6.7 million (up 12.23% YoY), while the FY2025 annual figure was $7.1 million, up 55.99% from the prior year.
• Non Operating Income advanced to $1.8 million in Q1 2026 per TARA's latest filing, from $1.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.2 million in Q1 2025 and bottomed at $119000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.0 million across 5 years, with a median of $846000.0 in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 1560.0% — and 2026, when it fell 16.43%.
• Protara Therapeutics' Non Operating Income stood at $542000.0 in 2022, then surged by 51.29% to $820000.0 in 2023, then surged by 88.17% to $1.5 million in 2024, then advanced by 14.84% to $1.8 million in 2025, then climbed by 4.23% to $1.8 million in 2026.
• Business Quant data shows TARA's Non Operating Income at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.5 million in Q3 2025.